Price Chart

Profile

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
URL https://www.exactsciences.com
Investor Relations URL https://investor.exactsciences.com/investor-relations/default.aspx
HQ State/Province Wisconsin
Sector Healthcare
Industry Diagnostics & Research
Equity Style Mid Cap/Growth
Next Earnings Release May. 09, 2024 (est.)
Last Earnings Release Feb. 21, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
URL https://www.exactsciences.com
Investor Relations URL https://investor.exactsciences.com/investor-relations/default.aspx
HQ State/Province Wisconsin
Sector Healthcare
Industry Diagnostics & Research
Equity Style Mid Cap/Growth
Next Earnings Release May. 09, 2024 (est.)
Last Earnings Release Feb. 21, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A